Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
EarlyCDT-Lung (Oncimmune) is a blood test that measures a group of 7 autoantibodies (p53, NYESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2) to tumour-associated antigens related to lungcancer. It helps early detection of lungcancer in people with high risk and allows differentiation of benign or malignant nodules. In the early stages of lungcancer, autoantibodies and tumour-associated antigens are produced as the body's immune system's response to cancer antigens. Blood levels of autoantibodies (...) . NICE's guideline on the diagnosis and management of lungcancer recommends sputum cytology for investigation in people with suspected lungcancer who have centrally placed nodules and are unable to tolerate bronchoscopy or invasive tests. A contrast-enhanced chest CT scan is recommended for further diagnosis and to stage the disease. The guideline recommends PET-CT as a first test after CT with a low probability of nodal malignancy (lymph nodes below 10 mm). MRI, endobronchial ultrasound-guided
A Systematic Review and Narrative Synthesis to Explore the Effectiveness of Exercise-Based Interventions in Improving Fatigue, Dyspnea, and Depression in LungCancer Survivors. Lungcancer survival rates are increasing; however, lungcancer survivors' mental and physical well-being can suffer from experiencing symptoms of fatigue, dyspnea, and depression. Exercise can improve these symptoms. However, no studies have examined the effects of different exercise interventions on these symptoms.This (...) review aims to examine the evidence on the effects of exercise interventions on fatigue, dyspnea, and depression in lungcancer survivors.PRISMA guidelines were followed. CINAHL, MEDLINE, EMBASE, and Cochrane databases were searched between 2000 and May 2017. Gray literature was searched. All identified studies were screened for inclusion. Quantitative data were narratively synthesized.From 852 records retrieved and screened, 10 full-text articles were included. Seven studies had a high risk of bias
countries. The results indicated that the expression of the MAGE-A gene was significantly correlated with lymph node metastases (RR 1.21, 95% CI 1.09-1.34; P = 0.001), high tumour-node-metastasis stage (RR 1.24, 95% CI 1.12-1.38; P < 0.001), histological type (squamous cell carcinoma) (RR 1.82, 95% CI 1.15-2.87; P = 0.01), poor overall survival (HR 2.11, 95% CI 1.73-2.57; P < 0.001) and cancer-specific survival (HR 1.76, 95% CI 1.12-2.78; P = 0.015). MAGE-A gene expression is related to tumour (...) The association of melanoma-associated antigen-A gene expression with clinicopathological characteristics and prognosis in resected non-small-cell lungcancer: a meta-analysis. Our goal was to explore the association of melanoma-associated antigen-A (MAGE-A) gene expression with clinicopathological parameters and survival rates in patients with non-small-cell lungcancer (NSCLC) who had surgery. A systematic search of EMBASE, PubMed, Web of Science and The Cochrane Library databases
PEBP4 gene expression in lung squamous cell carcinoma: A meta-analysis-based study of the molecular pathways involved. Previous studies have suggested increased activity of phosphatidylethanolamine binding protein 4 (PEBP4) may be associated with the prognosis of non-small cell lungcancer. However, to the best of our knowledge, no direct association between PEBP4 and lung squamous cell carcinoma (LSCC) has been reported. In the present study, a systematic review and meta-analysis was performed
Prognostic Impact of Tumor Spread Through Air Spaces in Non-small Cell LungCancers: a Meta-Analysis Including 3564 Patients. Surgical resection is the most effective treatment for early stage lungadenocarcinoma. However, the rate of 5-year postoperative recurrence reaches 30%, Spread Through Air Spaces(STAS) is a recently described novel invasive pattern of lungcancer, According to the 2015 WHO classification. STAS is defined as"micropapillary clusters, solid nests, or single cells spreading (...) within air spaces beyond the edge of the main tumor, However, the prognostic role of STAS in lungcancer is not known, The aim of the current study is to evaluate the association between STAS and clinical outcome of lungcancer patients after surgical resection through a meta-analysis. Systematic research was conducted using three online databases to search for studies published before August 1, 2018. The 5-year RFS and OS for non-small cell lungcancer patients after surgical resection
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lungcancer. A systematic review and network meta-analysis. This network meta-analysis (NMA), based on 12 phase-III studies with 9,236 metastatic NSCLC patients, aims to compare the efficacy of treatments including at least one immune-checkpoint inhibitor (ICI) with or without chemotherapy, as frontline therapy for advanced NSCLC patients. The NMA includes direct
18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lungcancer: a systematic review and meta-analysis. To evaluate the diagnostic test accuracy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), whole-body magnetic resonance imaging (WB-MRI), and whole-body diffusion-weighted imaging (WB-DWI) for the detection of metastases in patients with non-small cell lungcancer (NSCLC).MEDLINE, Embase, and Cochrane Library (...) -small cell lungcancer. • Whole-body MRI may be used as a non-invasive and radiation-free alternative to positron emission tomography with CT with similar diagnostic performance.
Effectiveness of Traditional Chinese Medicine on chemo-radiotherapy induced leukaemia in patients with lungcancer: a Meta-analysis. To assess the curative effect of Traditional Chinese Medicine (TCM) on leukopenia induced by chemo-radiotherapy in patients with lung cancer.A comprehensive electronic search in Medline, Embase, the Cochrane Libary database, China National Knowledge Infrastructure Database (CNKI) and Wanfang Database was conducted up to July 2017. Random-effects model was used (...) < 0.000 01].By meta-regression it was suggested that TCM has curative effect on leukopenia induced by chemo-radiotherapy in patients with lungcancer, but by the influence of number and quality of researches, publication bias, more evidence from high quality studies, and larger cohorts for observational trials are needed.
The Case for Patient Navigation in LungCancer Screening in Vulnerable Populations: A Systematic Review. Patient navigation has been proposed to combat cancer disparities in vulnerable populations. Vulnerable populations often have poorer cancer outcomes and lower levels of screening, adherence, and treatment. Navigation has been studied in various cancers, but few studies have assessed navigation in lungcancer. Additionally, there is a lack of consistency in metrics to assess the quality (...) of navigation programs. The authors conducted a systematic review of published cancer screening studies to identify quality metrics used in navigation programs, as well as to recommend standardized metrics to define excellence in lungcancer navigation. The authors included 26 studies evaluating navigation metrics in breast, cervical, colorectal, prostate, and lungcancer. After reviewing the literature, the authors propose the following navigation metrics for lungcancer screening programs: (1) screening
/j.ijsu.2019.11.034 Ain Qurat Ul QU Armed Forces Institute of Pathology, Rawalpindi, Pakistan. Electronic address: firstname.lastname@example.org. Majeed Numan N Department of pathology, Chemical Pathology Laboratory, Military Hospital, Rawalpindi, Pakistan. Electronic address: email@example.com. eng Letter Comment 2019 12 20 England Int J Surg 101228232 1743-9159 IM Int J Surg. 2019 Dec;72:175-184 31715310 Adenocarcinoma of Lung Frozen Sections Humans LungNeoplasms Pancreatectomy Declaration of competing (...) A commentary on "Intraoperative frozen section for identifying the invasion status of lungadenocarcinoma: A systematic review and meta-analysis" (Int J Surg 2019; 72:175-84). 31870752 2020 03 27 2020 03 27 1743-9159 74 2020 02 International journal of surgery (London, England) Int J Surg A commentary on "Intraoperative frozen section for identifying the invasion status of lungadenocarcinoma: A systematic review and meta-analysis" (Int J Surg 2019; 72:175-84). 2 S1743-9191(19)30370-X 10.1016
. For the prognosis analysis of miR-155 in lungcancer, the pooled HRs and 95% CIs of miR-155 for overall survival/disease free survival/progression-free survival (OS/DFS/PFS) were calculated. In addition, Subgroup and meta-regression analyses were performed to distinguish the potential sources of heterogeneity between studies.For the diagnostic analysis of miR-155 in lungcancer, the pooled SEN and SPE were 0.82 (95% CI: 0.72-0.88) and 0.78 (95% CI: 0.71-0.84), respectively. Besides, the pooled PLR was 3.75 (95 (...) The value of miR-155 as a biomarker for the diagnosis and prognosis of lungcancer: a systematic review with meta-analysis. Recently, a growing number of studies have reported the coorelation between miR-155 and the diagnosis and prognosis of lungcancer, but results of these researches were still controversial due to insufficient sample size. Thus, we carried out the systematic review and meta-analysis to figure out whether miR-155 could be a screening tool in the detection and prognosis
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lungcancer: A systematic review and critical appraisal. Uncommon epidermal growth factor receptor (EGFR) mutations collectively account for 10% of EGFR mutations, harboring heterogeneous molecular alterations within exons 18-21 with clinically variable responses to EGFR tyrosine kinase inhibitors (TKIs) in advanced Non-Small Cell LungCancer (NSCLC) patients. In addition, with the introduction
The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lungcancer. The present study aimed to evaluate the effect of liver metastases on the efficacy from the combination of PD-1/PD-L1 inhibitor with chemotherapy as first-line treatment in lungcancer using the meta-analysis. A total of 8 randomized controlled trials (RCTs) were included. In patients without liver metastases, PD-1/PD-L1 inhibitor plus chemotherapy could decrease the risk of progression by 40 (...) % and risk of death by 29% (HR = 0.60; 95%CI,0.55- 0.65 and HR = 0.71;95%CI,0.58-0.90 respectively). In patients with liver metastases, PD-1/PD-L1 inhibitor plus chemotherapy could decrease the risk of progression by 31% and risk of death by 21% (HR = 0.69;95%CI,0.58-0.81; and HR = 0.79; 95%CI,0.62-0.80, respectively). The pooled ratios of PFS-HRs and OS- HRs reported in lungcancer patients with liver metastases versus those without liver metastases were 1.11 (95%CI, 0.92-1.34) and 1.03 (95%CI, 0.80
Comparability of PD-L1 immunohistochemistry assays for non-small-cell lungcancer: a systematic review. Programmed cell death ligand 1 (PD-L1) immunohistochemistry is used to determine which patients with advanced non-small-cell lungcancer (NSCLC) respond best to treatment with PD-L1 inhibitors. For each inhibitor, a unique immunohistochemical assay was developed. This systematic review gives an up-to-date insight into the comparability of standardised immunohistochemical assays and laboratory (...) -developed tests (LDTs), focusing specifically on tumour cell (TC) staining and scoring. A systematic search was performed identifying publications that assessed interassay, interobserver and/or interlaboratory concordance of PD-L1 assays and LDTs in tissue of NSCLC patients. Of 4294 publications identified through the systematic search, 27 fulfilled the inclusion criteria and were of sufficient methodological quality. Studies assessing interassay concordance found high agreement between assays 22C3, 28
Front-line Therapy in Advanced Non-Small Cell LungCancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis. Several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were firmly established as front-line treatment for non-small cell lungcancer (NSCLC) that harbored an activating EGFR mutation. Gefitinib or erlotinib was considered the standard of care. TKI-based combination therapy has been investigated and has shown encouraging (...) results.The PubMed and EMBASE databases, the Cochrane Central Register of Controlled Trials, and meeting abstracts were screened for relevant studies between January 2000 and February 2019. Prospective randomized controlled trials were included that investigated EGFR TKIs (alone or in combination) in untreated patients with NSCLC whose tumors had sensitive EGFR mutations. A frequentist random effects network meta-analysis model was conducted to assess objective response rate, progression-free survival
Effects of Home-Based Exercise Training for Patients With LungCancer. To investigate the effectiveness of home-based exercise training on exercise capacity, dyspnea, anxiety, depression, and health-related quality of life (HRQOL).A systematic literature search of the Cochrane Central Register of Randomized Controlled Trials, Embase®, PubMed®, and Web of Science databases was performed for articles published through July 22, 2018.The meta-analysis was conducted with Review Manager, version 5.3 (...) , following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.10 articles with a total of 453 patients met the inclusion criteria. Home-based exercise training was found to increase the six-minute walk distance. In addition, anxiety was also improved after the intervention. However, no improvements in dyspnea, depression, or HRQOL were observed.Home-based exercise training as a nursing intervention for promoting the rehabilitation of patients with lungcancer can
Prognostic value of cripto-1 expression in non-small-cell lungcancer patients: a systematic review and meta-analysis. Aim: This systematic review and meta-analysis aimed to analyze the association between cripto-1 expression and prognosis as well as clinicopathological features of non-small-cell lungcancer (NSCLC) patients. Methods: The electronic databases for all articles about NSCLC and cripto-1 expression were searched. Results: Twelve articles were enrolled in this meta-analysis (3130